MCID: GSG001
MIFTS: 51

Gas Gangrene

Categories: Infectious diseases, Muscle diseases

Aliases & Classifications for Gas Gangrene

MalaCards integrated aliases for Gas Gangrene:

Name: Gas Gangrene 12 54 43 15 37 17 71 32
Myonecrosis 12 71
Gas Bacillus Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9159
ICD9CM 34 040.0
MeSH 43 D005738
SNOMED-CT 67 80466000
ICD10 32 A48.0
UMLS 71 C0017105 C0235957

Summaries for Gas Gangrene

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection, located in muscle tissue, has material basis in Clostridium perfringens, which produce gas that becomes trapped in the infected tissue. Gas gangrene usually develops after injuries or surgery. The infection has symptom large blisters, has symptom pain in the infected area, has symptom myonecrosis, has symptom gas production, and has symptom sepsis.

MalaCards based summary : Gas Gangrene, also known as myonecrosis, is related to myoglobinuria and compartment syndrome, and has symptoms including myoclonus, torticollis and muscle cramp. An important gene associated with Gas Gangrene is HSPG2 (Heparan Sulfate Proteoglycan 2), and among its related pathways/superpathways are Pancreatic secretion and Striated Muscle Contraction. The drugs Cilostazol and Tirofiban have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, liver and heart, and related phenotypes are cardiovascular system and muscle

Wikipedia : 74 Gas gangrene (also known as clostridial myonecrosis and myonecrosis) is a bacterial infection that... more...

Related Diseases for Gas Gangrene

Diseases related to Gas Gangrene via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 myoglobinuria 30.8 PIK3C2A MB DMD
2 compartment syndrome 30.7 PIK3C2A MB CRP
3 disseminated intravascular coagulation 30.6 PIK3C2A MB CRP CPB2
4 acute pancreatitis 30.6 SERPINA3 PLA2G2A CRP CPB1
5 pyomyositis 30.6 PIK3C2A MB CRP
6 myositis 30.5 SERPINA3 PIK3C2A MB DMD
7 clostridium difficile colitis 30.5 PSMA6 CRP ALLC
8 myocarditis 30.5 TNNI3 PIK3C2A MB DMD
9 toxic myocarditis 30.5 TNNI3 PIK3C2A
10 anuria 30.3 PIK3C2A MB CRP
11 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 30.3 PIK3C2A MB
12 endocarditis 30.2 TNNI3 PIK3C2A CRP
13 arteries, anomalies of 30.2 TNNT2 TNNI3 SERPINA3 CRP
14 pericarditis 30.1 TNNT2 TNNI3 CRP
15 angina pectoris 30.1 TNNI3 PIK3C2A MB CRP
16 atrial standstill 1 30.0 TNNT2 TNNI3 DMD
17 respiratory failure 29.8 SERPINA3 PIK3C2A DMD CRP
18 pneumonia 29.8 PIK3C2A NEU1 MB CRP
19 acute myocardial infarction 29.8 TNNT2 TNNI3 PIK3C2A MB CRP
20 muscular dystrophy, duchenne type 29.8 TNNT2 TNNI3 PIK3C2A MYOD1 MB DMD
21 muscular dystrophy 29.7 TNNT2 TNNI3 PIK3C2A MYOD1 MB HSPG2
22 hypertrophic cardiomyopathy 29.7 TNNT2 TNNT1 TNNI3 DMD
23 coronary artery anomaly 29.4 TNNT2 TNNT1 TNNI3 PIK3C2A MB EEF1A2
24 pulmonary embolism 29.3 TNNT2 TNNT1 TNNI3 MB CRP CPB2
25 intermediate coronary syndrome 29.1 TNNT2 TNNT1 TNNI3 PIK3C2A MB EEF1A2
26 myocardial infarction 28.7 TNNT2 TNNT1 TNNI3 SERPINA3 PSMA6 PIK3C2A
27 anthrax disease 11.5
28 virus associated hemophagocytic syndrome 10.6 PIK3C2A MB
29 myositis fibrosa 10.6 PIK3C2A MB
30 anterior compartment syndrome 10.5 PIK3C2A MB
31 tetanus 10.5
32 posterior myocardial infarction 10.5 PIK3C2A MB
33 anteroseptal myocardial infarction 10.5 PIK3C2A MB
34 malignant granular cell myoblastoma 10.5 SERPINA3 MB
35 familial isolated restrictive cardiomyopathy 10.5 TNNT2 TNNI3
36 orbital plasma cell granuloma 10.5 PIK3C2A CRP
37 cellulitis 10.5
38 progressive muscular dystrophy 10.4 MB DMD
39 chronic thromboembolic pulmonary hypertension 10.4 CRP CPB2
40 surfactant dysfunction 10.4 PLA2G2D PLA2G2A
41 toxic shock syndrome 10.4
42 orbit rhabdomyosarcoma 10.4 MYOG MB
43 legionnaire disease 10.4 SERPINA3 PIK3C2A CRP
44 commensal bacterial infectious disease 10.4 PSMA6 PLA2G2A CRP
45 coronary artery vasospasm 10.4 TNNI3 PIK3C2A CRP
46 cardiac tamponade 10.4 TNNI3 PIK3C2A CRP
47 ornithosis 10.4 PIK3C2A ALLC
48 aspiration pneumonitis 10.4 SERPINA3 CRP
49 creatine phosphokinase, elevated serum 10.4 PIK3C2A MB DMD
50 rheumatic myocarditis 10.4 TNNT2 TNNI3 CRP

Comorbidity relations with Gas Gangrene via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Peripheral Vascular Disease

Graphical network of the top 20 diseases related to Gas Gangrene:



Diseases related to Gas Gangrene

Symptoms & Phenotypes for Gas Gangrene

UMLS symptoms related to Gas Gangrene:


myoclonus, torticollis, muscle cramp

MGI Mouse Phenotypes related to Gas Gangrene:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 CPE CRP DMD HSPG2 MB MYOD1
2 muscle MP:0005369 9.7 CPE DMD EEF1A2 HSPG2 MB MYOD1
3 respiratory system MP:0005388 9.23 CPB2 DMD HSPG2 MB MYOD1 MYOG

Drugs & Therapeutics for Gas Gangrene

Drugs for Gas Gangrene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Tirofiban Approved Phase 4 144494-65-5 60947
3
Dipyridamole Approved Phase 4 58-32-2 3108
4
Colchicine Approved Phase 4 64-86-8 6167 2833
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
9 Neurotransmitter Agents Phase 4
10 Vasodilator Agents Phase 4
11 Purinergic P2Y Receptor Antagonists Phase 4
12 Anti-Asthmatic Agents Phase 4
13 Respiratory System Agents Phase 4
14 Autonomic Agents Phase 4
15 Protective Agents Phase 4
16 Neuroprotective Agents Phase 4
17 Bronchodilator Agents Phase 4
18 Phosphodiesterase 3 Inhibitors Phase 4
19 Phosphodiesterase Inhibitors Phase 4
20 Pharmaceutical Solutions Phase 4
21 Antimitotic Agents Phase 4
22 Hypolipidemic Agents Phase 4
23 Anticholesteremic Agents Phase 4
24 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
25 Lipid Regulating Agents Phase 4
26 Antimetabolites Phase 4
27 Analgesics Phase 4
28 Platelet Aggregation Inhibitors Phase 4
29 Fibrinolytic Agents Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Antipyretics Phase 4
34 Cyclooxygenase Inhibitors Phase 4
35 Antirheumatic Agents Phase 4
36
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
37
Bivalirudin Approved, Investigational Phase 3 128270-60-0 16129704
38
Ticagrelor Approved Phase 3 274693-27-5 9871419
39
Adenosine Approved, Investigational Phase 3 58-61-7 60961
40
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
41
protease inhibitors Phase 3
42 HIV Protease Inhibitors Phase 3
43 Antithrombins Phase 3
44 Serine Proteinase Inhibitors Phase 3
45 Anticoagulants Phase 3
46 Hirudins Phase 3
47 calcium heparin Phase 3
48 Antithrombin III Phase 3
49 Rosuvastatin Calcium Phase 3 147098-20-2
50 Calcium, Dietary Phase 3

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS) Unknown status NCT01430377 Phase 4
2 BIfurcation Optimal Treatment Strategy With LIMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study Unknown status NCT01430364 Phase 4
3 ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome Completed NCT01354808 Phase 4 Dual Anti-Platelet Therapy (DAPT);Triple Anti-Platelet Therapy (TAPT)
4 Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent Completed NCT01498003 Phase 4 tirofiban;normal saline solution
5 Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI Completed NCT00767663 Phase 4 dipyridamole;placebo
6 Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism Completed NCT00915733 Phase 4 cilostazol;clopidogrel (Plavix);aspirin (Acetylsalicylic acid)
7 Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention: Inflammatory Marker Substudy of the Colchicine-PCI Trial Active, not recruiting NCT01709981 Phase 4 Colchicine;Placebo
8 Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance Terminated NCT00289601 Phase 4 eptifibatide
9 Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study Terminated NCT00344019 Phase 4 Placebo Oral Tablet;Atorvastatin 80mg
10 Randomized Comparison of Adenosin Intracoronary Infusion and Clopidogrel Pretreatment on Myonecrosis Occurence in Elective PCI Unknown status NCT00751491 Phase 3 Adenosin;Clopidogrel
11 Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial Unknown status NCT01555658 Phase 3 Bivalirudin;Unfractioned Heparin
12 High Loading ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis : Comparison With Atorvastatin High Dose Reloading. Completed NCT01228227 Phase 3 ATORVASTATIN 80 mg;ROSUVASTATIN 40 mg
13 Prevention of Cardiac and Vascular Periprocedural Complications in Patients Undergoing Coronary Angiography or Angioplasty: Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty. A Prospective Double-blind Randomized Trial. Completed NCT01148147 Phase 3 Adenosine;Placebo
14 ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis Completed NCT01007279 Phase 3 ROSUVASTATIN
15 Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention. Recruiting NCT01930773 Phase 3
16 Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study Recruiting NCT02617290 Phase 3 Ticagrelor;Clopidogrel
17 Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis Terminated NCT00612521 Phase 3 Adenosine
18 A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema Unknown status NCT01794182 Phase 2 RP-1127 (Glyburide for Injection)
19 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
20 A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
21 Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG Unknown status NCT03383393 Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
22 Assessment of Vessel Healing After DES Implantation With STEMI, NSTEMI and Stable/Unstable Angina Patients: a Randomized Study Between Everolimus and Biolimus A9-eluting Stents: an Optical Coherence Tomography (OCT) and Intravascular Ultrasound Tissue Characterisation (IVUS-TC) Study Unknown status NCT01065519
23 COronary SIde Branch Residual IschemiA and COllateralization Assessment Study (COSIBRIA & Co Study) Completed NCT01268228
24 Biomarkers in Necrotizing Soft Tissue Infections - Effects of Hyperbaric Oxygen Treatment on the Immune Response Completed NCT02501382
25 Remote Myocardial Ischemic Preconditioning in Humans Completed NCT00588042
26 Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome Completed NCT02054390
27 Biomarkers in Necrotizing Soft Tissue Infections - Aspects of the Innate Immune Response Completed NCT02180906
28 Prospective Partially Randomized Comparison of Clopidogrel Loading Versus Maintenance Dosing to Prevent Periprocedural Myocardial Infarction After Stenting for a Stable Angina Pectoris Completed NCT03759067 clopidogrel 75mg;Clopidogrel 300 mg;clopidogrel 600mg
29 ProTreat - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study Completed NCT03147352
30 Fractional Flow Reserve Versus Intracoronary ECG for Detection of Post Stenting Ischemia in Side Branch Territory in coronAry Bifurcation Lesions Recruiting NCT01724957
31 Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke Recruiting NCT03431402 Hyperbaric oxygen
32 The Bioelectrical Impedance Analysis and Muscular Ultrasound in the Detection of Nutritional Status in Critically Ill Patients: The BUS Study Recruiting NCT03924232
33 The Registry of Hyperbaric Oxygen Therapy Treated Patients Enrolling by invitation NCT02483650
34 Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI Terminated NCT00979940 Atorvastatin

Search NIH Clinical Center for Gas Gangrene

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Gas Gangrene cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Gas Gangrene:
Peripheral blood-derived hematopoietic stem cells for leg gangrene
Embryonic/Adult Cultured Cells Related to Gas Gangrene:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: gas gangrene

Genetic Tests for Gas Gangrene

Anatomical Context for Gas Gangrene

MalaCards organs/tissues related to Gas Gangrene:

40
Skeletal Muscle, Liver, Heart, Colon, Skin, Bone, Brain

Publications for Gas Gangrene

Articles related to Gas Gangrene:

(show top 50) (show all 3075)
# Title Authors PMID Year
1
Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens. 54 61
18160514 2008
2
Clostridium perfringens phospholipase C-induced platelet/leukocyte interactions impede neutrophil diapedesis. 54 61
16585634 2006
3
Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens. 54 61
10950774 2000
4
The antibiotic susceptibility pattern of gas gangrene-forming Clostridium spp. clinical isolates from South-Eastern Hungary. 61
31778089 2020
5
Immunization of rabbits with recombinant Clostridium perfringens alpha toxins CPA-C and CTB-CPA-C in a bicistronic design expression system confers strong protection against challenge. 61
31811913 2020
6
The EngCP endo α-N-acetylgalactosaminidase is a virulence factor involved in Clostridium perfringens gas gangrene infections. 61
31987726 2020
7
Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis. 61
31894484 2020
8
Myotoxicity induced by Cerastes cerastes venom: Beneficial effect of heparin in skeletal muscle tissue regeneration. 61
31738878 2020
9
Comparative study of calcium and calcium-related enzymes with differentiation markers in different ages and muscle types in mdx mice. 61
31274171 2020
10
Generation of recombinant baculovirus expressing atoxic C-terminal CPA toxin of Clostridium perfringens and production of specific antibodies. 61
31992276 2020
11
[Interesting Case: Sucking wound of the upper limb simulating gas-gangrene]. 61
31931545 2020
12
Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). 61
32029306 2020
13
Gas Gangrene of the Gallbladder. 61
32031512 2020
14
Expansile calcific myonecrosis arising in the lower leg: A case report and recommendation for treatment. 61
31870641 2019
15
Novel infectious myonecrosis virus (IMNV) genotypes associated with disease outbreaks on Penaeus vannamei shrimp farms in Indonesia. 61
31531743 2019
16
Immunolabelling Myofiber Degeneration in Muscle Biopsies. 61
31868171 2019
17
Inflammasome Activation Induced by a Snake Venom Lys49-Phospholipase A2 Homologue. 61
31906173 2019
18
Clostridium septicum Myonecrosis Secondary to an Occult Small Bowel Adenocarcinoma. 61
30198050 2019
19
Relationship Between Platelet Reactivity and Periprocedural Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. 61
31786528 2019
20
Clostridium septicum-infected aortic aneurysm or graft is a deadly diagnosis. 61
31843297 2019
21
Immune-mediated necrotising myopathy: A critical review of current concepts. 61
31109639 2019
22
Cardiac and skeletal muscle changes associated with rosuvastatin therapy in dystrophic mdx mice. 61
31855314 2019
23
Fatal lancehead pit viper (Bothrops spp.) envenomation in horses. 61
31499078 2019
24
Calcified or ossified benign soft tissue lesions that may simulate malignancy. 61
31297550 2019
25
Spontaneous non-traumatic Clostridium perfringens sepsis. 61
31875607 2019
26
Vegetative Endocarditis due to Staphylococcus aureus in an Umbrella Cockatoo (Cacatua alba). 61
31833311 2019
27
Erratum to 'Don't Move a Muscle: A Case of Diabetic Myonecrosis'. 61
31630770 2019
28
Thermophile Lytic Enzyme Fusion Proteins that Target Clostridium perfringens. 61
31717357 2019
29
Photobiomodulation reduces cell death and cytokine production in C2C12 cells exposed to Bothrops venoms. 61
31754908 2019
30
Inactivated recombinant Escherichia coli as a candidate vaccine against Clostridium perfringens alpha toxin in sheep. 61
31299397 2019
31
Gas gangrene as a surgical emergency - own experience. 61
31849354 2019
32
Light emitting diode (LED) photobiomodulation therapy on murine macrophage exposed to Bothropstoxin-I and Bothropstoxin-II myotoxins. 61
31693915 2019
33
Isolation of two basic phospholipases A2 from Bothrops diporus snake venom: Comparative characterization and synergism between Asp49 and Lys49 variants. 61
31326508 2019
34
Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. 61
31591596 2019
35
Hereditary spherocytosis: a risk factor for thigh pressure myonecrosis in posterior spine surgery. 61
31651750 2019
36
Clostridium sordellii-associated gas gangrene in eight horses, 1998-2019. 61
31585515 2019
37
Evidence for Infections by the Same Strain of Beta 2-toxigenic Clostridium perfringens Type A Acquired in One Hospital Ward. 61
31880878 2019
38
Biopsy-Proven Myonecrosis in the Right Forearm of a Type 2 Diabetic Woman. 61
29742536 2019
39
Myonecrosis: A Rare Complication of Cryoneurolysis. 61
31400988 2019
40
Vaccine Production to Protect Animals Against Pathogenic Clostridia. 61
31514424 2019
41
Granulocyte Colony-Stimulating Factor Does Not Influence Clostridium Perfringens α-Toxin-Induced Myonecrosis in Mice. 61
31480318 2019
42
Upper-Limb Diabetic Myonecrosis: Atypical Presentation of a Rare Complication. 61
31455756 2019
43
Deficient Skeletal Muscle Regeneration after Injury Induced by a Clostridium perfringens Strain Associated with Gas Gangrene. 61
31138614 2019
44
Type A fulminant Clostridium perfringens sepsis indicated RBC/Hb discrepancy; a case report. 61
31416426 2019
45
Calcific Myonecrosis of the Leg: A Rare Entity. 61
31466356 2019
46
Necrotizing Fasciitis: Low-Dose Radiotherapy as a Potential Adjunct Treatment. 61
31496924 2019
47
Diabetic Myonecrosis: A Poorly Recognized Complication in an Adult With Type 2 Diabetes. 61
31474461 2019
48
Evaluation of the Inhibitory Potential of Casuarictin, an Ellagitannin Isolated from White Mangrove (Laguncularia racemosa) Leaves, on Snake Venom Secretory Phospholipase A2. 61
31288445 2019
49
Neurotoxicity of Micrurus lemniscatus lemniscatus (South American coralsnake) venom in vertebrate neuromuscular preparations in vitro and neutralization by antivenom. 61
31123802 2019
50
Hyperbaric oxygen therapy in Plastic Surgery practice: case series and literature overview. 61
32011977 2019

Variations for Gas Gangrene

Expression for Gas Gangrene

Search GEO for disease gene expression data for Gas Gangrene.

Pathways for Gas Gangrene

Pathways related to Gas Gangrene according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.27 PLA2G2D PLA2G2A CPB2 CPB1
2 10.78 TNNT2 TNNT1 TNNI3 DMD

GO Terms for Gas Gangrene

Cellular components related to Gas Gangrene according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 SERPINA3 PLA2G2D PLA2G2A NEU1 HSPG2 CRP
2 extracellular exosome GO:0070062 9.97 SERPINA3 PSMA6 PLA2G2A PIK3C2A NEU1 MB
3 sarcomere GO:0030017 9.54 TNNT2 TNNI3 PSMA6
4 cardiac myofibril GO:0097512 9.26 TNNT2 TNNI3
5 cardiac Troponin complex GO:1990584 9.16 TNNT2 TNNI3
6 troponin complex GO:0005861 9.13 TNNT2 TNNT1 TNNI3
7 myofibril GO:0030016 9.02 TNNT2 TNNI3 PSMA6 MYOD1 DMD

Biological processes related to Gas Gangrene according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 muscle contraction GO:0006936 9.71 TNNT2 TNNT1 TNNI3
2 muscle organ development GO:0007517 9.7 MYOG MYOD1 DMD
3 skeletal muscle tissue development GO:0007519 9.58 MYOG MYOD1 DMD
4 phosphatidylglycerol acyl-chain remodeling GO:0036148 9.55 PLA2G2D PLA2G2A
5 myotube differentiation GO:0014902 9.51 MYOG MYOD1
6 skeletal muscle contraction GO:0003009 9.5 TNNT2 TNNT1 TNNI3
7 negative regulation of ATPase activity GO:0032780 9.49 TNNT2 TNNI3
8 response to denervation involved in regulation of muscle adaptation GO:0014894 9.48 MYOG DMD
9 positive regulation of skeletal muscle fiber development GO:0048743 9.46 MYOG MYOD1
10 muscle cell fate commitment GO:0042693 9.43 MYOG MYOD1
11 myotube cell development GO:0014904 9.37 MYOD1 DMD
12 regulation of muscle contraction GO:0006937 9.33 TNNT2 TNNT1 TNNI3
13 slow-twitch skeletal muscle fiber contraction GO:0031444 9.26 TNNT1 MB
14 cardiac muscle contraction GO:0060048 9.26 TNNT2 TNNT1 TNNI3 DMD
15 muscle filament sliding GO:0030049 8.92 TNNT2 TNNT1 TNNI3 DMD

Molecular functions related to Gas Gangrene according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 10.01 PSMA6 PLA2G2D PLA2G2A NEU1 CPE CPB2
2 calcium ion binding GO:0005509 9.85 TNNT2 TNNT1 PLA2G2D PLA2G2A HSPG2 CRP
3 calcium-dependent phospholipase A2 activity GO:0047498 9.46 PLA2G2D PLA2G2A
4 tropomyosin binding GO:0005523 9.43 TNNT2 TNNT1
5 troponin T binding GO:0031014 9.32 TNNT1 TNNI3
6 calcium-dependent ATPase activity GO:0030899 9.26 TNNT2 TNNT1
7 troponin C binding GO:0030172 9.16 TNNT2 TNNI3
8 metallocarboxypeptidase activity GO:0004181 9.13 CPE CPB2 CPB1
9 carboxypeptidase activity GO:0004180 8.8 CPE CPB2 CPB1

Sources for Gas Gangrene

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....